BACKGROUND Triple-negative breast cancer (TNBC) patients generally have poor prognosis but could be led to a better outcome if the risk can be identified in the stage without symptoms. Previously, determining the hereditary risk relied solely on assessing the potential damage due to single mutations or individually damaged genes, which has led to fragmentation in our understanding of genetic risk, particularly when multiple factors are involved. It is currently difficult to obtain a complete picture of genetic risk that unites individual discoveries under a single theoretical frame, not to mention a category method for systematically assessing all individuals within a population.
Introduction
According to data from the China National Central Cancer Registry, the incidence (268,600 new cases in 2015) and mortality (69,500 death cases in 2015) of breast cancer has continued to increase in China over the past two decades, and is fast becoming a major health concern in women. 1,2 Triple-negative breast cancer (TNBC) is defined by ≤ 1% estrogen receptor positive tumor cells, progesterone receptor negativity, and normal HER2-receptor expression detected by immunohistochemistry or in situ hybridization analysis (separately or combined). 3 Among all types of breast cancer, TNBC makes up 15%-20% of cases, usually affecting younger women. 4 Compared with other types of breast cancer, patients with TNBC generally have poor prognosis due to the combination of its inherent aggressive clinical behavior and lack of molecular targets for therapy. 5, 6 On the other hand, studies have shown that screening and appropriate treatment can reduce breast cancer mortality. The contribution of screening and treatment in reducing cancer mortality differs according to the breast cancer subtype, of which the TNBC subtype benefits the most. 7 This has spurred major efforts in identifying potential molecular features that can be used to assess the risk for TNBC for surveillance, early detection, and timely treatment. The goal is a better outcome to prolong survival in patients with TNBC and to reduce TNBC-specific mortality. 7, 8 Identification of patients at risk for TNBC by genetic testing has been proven to help reduce breast cancer mortality. 9 Correspondingly, using a small number of highpenetrance mutations with a much larger number of low-penetrance variants to build a risk model for breast cancer is widely accepted. Much effort has focused on trying to identify and characterize high-and low-penetrance susceptibility genes. The well-known inherited BRCA1/2 (Breast Cancer genes 1 and 2) mutations are considered to be the most powerful predictors of the risk of developing breast cancer. 10, 11 However, those studies have proven to be very complex and they have not provided conclusive data. 12 Furthermore, BRCA1/2, the known high-penetrance genes account for no more than 25% of breast cancer cases based on prior studies and mathematical modeling. 13, 14 The remaining more than 75% of the familial risk for breast cancer is still unexplained and the extent of the contribution of an individual's genotype to the risk for breast cancer 10 is still unknown. Moreover, healthy women with breast cancer risk genotypes, but without symptoms, are not included in the current risk models.
In this paper, we postulated a persistent stress from certain deterministic pathogenic factors on the whole population, so that we can simply solve the problem by assessing the innate stress resistance in each individual. This resistance is encoded in germline DNA and can be disrupted by rarely occurring mutations in certain genes. We developed a multiple-step method to statistically infer the resistance for each individual by measuring function of a set of pathways disrupted by any rare mutations.
Consequently, a population without symptoms could be categorized into 5 resistance levels, in which 4.45% were classified as very high risk/very low resistance and, amazingly, up to 25% were classified as zero risk/fully protected. Interestingly, lymph node status is strongly associated with the five levels. Our method provides a new way to truly understand the nature of health and the possibly final weapon inside us against cancers.
Methods

Study design and patients
The general design of the study is presented in Fig. 1 . This study was approved by the research ethics committee at Guangdong General Hospital, Guangdong Academy of Medicals Sciences. Written informed consent was obtained from all participants to allow the use of banked tissues (including white blood cells and oral epithelial cells), and for collection of pathological data and clinical follow-up data. The characteristics of the TNBC patients are described in supplemental Table 1 .
Whole-exome sequencing
Oral epithelial cells or peripheral blood leukocytes were collected from individuals.
Each sequenced sample was prepared according to the Illumina protocols. Paired-end multiplex sequencing of samples was performed on the Illumina HiSeq X Ten sequencing platform.
Variant calling
Paired-end raw sequence reads were mapped to the human reference genome (UCSC hg19) using Burrows-Wheeler Aligner 15 using default settings. Variants calling was carried out using the HaplotypeCaller module in Genome Analysis Toolkit 16 following GATK Best Practices. The variants then were annotated by ANNOVAR 17 based on RefGene.
Variant coding
Genes were coded as 1 or 0 based on whether or not there was any mutation in the gene. The Z-score was calculated using both mutation and expression data from the COSMIC Cell Line Project. 18 Briefly, for each gene, all cell lines were separated into two groups based on whether or not they carried this gene mutation, and the differences between the average expression of each gene could then be calculated. We randomly assigned group labels to each cell line while maintaining group size, and then calculated the difference between the two simulated groups. This process was repeated 10000 times and the Z-score was calculated as the standardized value of the difference in the average expression.
Where μ and σ are the mean and standard deviation, respectively.
Statistical analysis
Method implemented in NMRCLUST 19 was used for clustering. This method uses the average linkage to define how clusters are built up, followed by penalty function that simultaneously optimizes the number of clusters and the average spread of the clusters. Naïve bayes 20 that was implemented in R package caret 21 was used to build the binary classifiers. We first randomly split the data into training group (75%) and testing group (25%) while preserve the overall class distribution of the data. Then the 10-fold cross validation was used to search the optimal parameters. All statistical analyses were conducted using an in-house developed script in Perl, Matlab, and R.
Results
The study recruited 29 TNBC patients and 112 healthy aged women (78.49 ± 1.24 years). We found 10 7 SNPs from their genomic DNA of each subject, of which 10 4 were rare (MAF < 0.01) germline mutations, which were used for coding. Those rare germline variants were coded into around 300 genes with mutations ( Fig. 1, left panel). Using the reference database ( Fig. 1, right panel) , we expanded the number of deterministically regulated expression genes to about 1000 which will be compared to the signatures of cancer related pathways. Finally, we projected the rare germline variants onto a spectrum of active/resting pathways less than one hundred.
Rare germline mutation profiles are exceptionally sparse
A germline variant with a frequency of less than 0.01 was defined as a rare germline variant. The average numbers of genes with rare germline variants in healthy people ranged from 220 to 300 as shown in Fig. 2B , which appeared to have a normal distribution. When comparing the number of mutated genes between any two individuals, we found between 4 and 34 shared genes, which also appeared to have a normal distribution ( Fig. 2C ). This suggests that most people have about 220 to 300 genes with rare germline variants, but there were only about 4 to 34 common mutated genes between any two individuals.
These rare variants were then coded into genes. In the cluster diagram ( Fig. 2A ), the variants in the genes were high-dimensional, sparse, discrete, and nonstandard.
Almost no similar variation patterns were observed between any two individuals, which indicated each person was unique. This is well illustrated in the upper panel of Fig. 2F . The Pearson correlation coefficient histogram was narrow and evenly distributed toward zero with a median value was < 0.05. Therefore, few rules could be inferred based on their gene mutation patterns, even being given sharp and meaningful phenotypes in current subjects.
We next coded the variants by their presence in cancer dependencies 22 and clustered them based on their effect on gene expression. We could infer, to some extent, a little more regularity from the cluster diagram (Fig. 2D ). The correlation coefficient histogram shifted to the right of the X-axis and the range extended to from -0.3 to 0.5 When the rare variants effect on gene expression were projected onto the pathway activity, we observed better clustering ( Fig. 2E ). The correlation coefficient histogram was no longer a normal distribution and shifted more to the right of the X-axis and the range extended to from -0.5 to 0.9, with a median value was 0.5 ( Fig. 2F, lower panel) .
When the germline variant information was gradually mapped onto the lowdimensional functional feature space, the internal regularity of the population gradually increased, suggesting that individuals with similar phenotypes might follow the same rules in this low-dimensional feature space.
Most pathways are downregulated in TNBC patients
When we projected the rare germline variants of the 29 TNBC patients onto those pathways, the cluster diagram showed a regular pattern (Fig. 3A) . However, the patterns in the cluster diagram appeared to be complex and could not be generalized by specific pathways. Next, we compared the pathway activities between the 112 healthy people and the 29 TNBC patients to try to characterize the features in TNBC patients. The upregulated pathways activity did not contribute to TNBC patient clustering ( Fig. 3B , asterisk line), whereas the downregulated pathways activity greatly contributed to the TNBC clustering ( Fig. 3B , dot line). When each pathway's activity was further examined (Fig. 3C ), we found 83% of the pathway activities were downregulated, indicating a repressed trend in most pathways in TNBC. In addition, the Z-score cutoff value tended to the minimum (Fig. 3B) , the more the pathway activity was downregulated, suggesting the risk/resistance for TNBC could be predicted by a small number of pathways. With the Z-score cutoff value set to -4 ( Fig.   3D ), the risk/resistance of TNBC could be predicted by just three pathways.
Three pathways can predict the risk of TNBC
To test our model, we chose three repressed pathways to predict the risk/resistance of TNBC. From Fig. 4A , we can see the average AUC appears to be a normal distribution, with a median value of 0.75. Fig. 4B shows the ROC curve with 95% confidence interval (CI) of false positive rate. With Z-score cutoff values set as from -1 to 0, the prediction accuracy was more than 70% ( Fig. 4C ) and false discovery rate was less than 30% ( Fig. 4D ), indicating high efficacy for predicting TNBC risk/resistance by three downregulated pathways.
Clustering people into five categorizes base on three pathways
We used the germline features of the three identified pathways to categorize the pooled study sample (112 healthy people and 29 TNBC patients) into groups corresponding to the level of TNBC risk/resistance. The result suggested that the appropriate number of cluster groups was 16 with a penalty < 22 (Fig. 5A ). For each group, we compared the proportion, Z score, and ratio of proportions between healthy people and TNBC patients (Fig. 5B ), and found some groups had values that were very close. The groups with similar values were then combined to give the final five groups (Fig. 5C ), which indicated five different levels of TNBC risk/resistance in this population. We found 31.03% TNBC patients and 4.45% healthy people fell into class 1 (very high risk/very low resistance) with a Z-score of 8, which indicated those with this pathway pattern had a TNBC risk/resistance about eight standard deviations above/below the mean risk/resistance. The proportion of TNBC patients was more than twice compared to the proportion of healthy people in class 2 (high risk/low resistance). Class 3 (average risk/resistance) included similar proportions of healthy people and TNBC patients, which suggested the risk of TNBC in this group was not related to germline variants. Notably, healthy people in class 4 (low risk/high resistance) might have protective factors against TNBC, as they had a lower risk of TNBC. Likewise, class 5 (zero risk) included 25% healthy people, but no TNBC patients, which indicated those with this pathway pattern had no risk of TNBC. In terms of predictive value, 4.45% healthy people (class 1) had very high risk/very low resistance of TNBC, which indicated the elimination trend; 16% healthy people (class available at http://philrivers.vicp.io:9900/.
Risk/Resistance classes are associated with lymph node metastasis
Next, we analyzed the clinical features of the TNBC patients. We observed a strong association (r 2 = 0.99, p = 0.0035) between Lymph node status and the five classes ( Fig. 5D , right panel). We found 67% patients in class 1 had lymph node metastasis, indicating aggressive pathway activity patterns. Likewise, 44% patients in class 2 and 25% in class 3 also had lymph node metastasis. No patients in class 4 had lymph node metastasis. Correspondingly, the median onset age of patients in class 1 was younger than that in class 2 and 3 but is not statistical significant (Fig. 5E ). To a certain extent, we were able to confirm the activation of these three pathways was related to the risk of TNBC and its progression.
Discussion
The aim of this study was to gain a deeper understanding of the genetic features of TNBC. With regards to gene mutations, gene expressions, and cancer pathways, we found the distance between genetic codes of any two individuals was generally becoming closer. When we projected the rare germline variants onto cancer pathways, significant genetic features were identified in the 29 TNBC patients. Furthermore, when pooling all 112 healthy people and 29 TNBC patients, we were able classify them into five risk/resistance groups for TNBC based on three repressed pathways. In these five groups, each individual with a certain pathway activity pattern had a different degree of risk/resistance for TNBC (in a spectrum from very high to zero risk). People with low or no risk (class 4 and 5) might have protective factors against TNBC, whereas those with very high risk/low resistance (class 1) will develop TNBC. Surprisingly, the risk/resistance patterns were closely associated with lymph node status, and very high risk/low resistance patients (class 1) tended to have lymph node metastasis, whereas low risk/high resistance patients (class 4) did not have lymph node metastasis, even in those with the same tumor staging. Because lymph node status has been identified as a significant independent prognostic factor for TNBC progress, mortality, and overall survival, 23-25 our rare germline variants-based risk/resistance patterns can be correlated to TNBC prognosis. The results may have important implications for our understanding of TNBC pathogenesis, allowing more aggressive treatments and monitoring of certain subgroups at risk of TNBC.
Cancer is a complex genetic disease that is a result of the accumulation of genomic alterations. 26 Germline variations predispose individuals to cancer and somatic alterations initiate and trigger the progression of cancer. 26 Although genetic data, especially rare variants, could provide useful risk prediction, 27 more efficient and accurate genetic-association models need to be established. We know that DNA and its structure holds massive amounts of information, which can be represented by binary values (on or off 28 ). Changes in multiple DNA sequences could contribute to one gene expression ("many to one"). Therefore, gene expression is continuous and informative. In this study, we collected all rare genetic variants in 112 healthy people and coded those rare variants into gene expressions. We obtained more regular patterns compared with gene mutation patterns. However, the data from rare genetic variants were high-dimensional and nonstandard. When we projected the genetic rare events onto cancer pathways, the cluster diagram appeared to be regular. We also showed that several individuals with similar phenotypes might share similar pathway activity patterns. Using this method, we found many TNBC patients shared similar characteristics and cancer pathways. When we compared the pathway patterns between healthy people and TNBC patients, we found three repressed pathways in TNBC. Surprisingly, based on only these three pathway activity patterns, we were able to grade the TNBC risk/resistance into different classes of risk/resistance. Most importantly, using this model, we were able to definitively identify subpopulations that have high risk for TNBC and those that have no risk.
Our model is a multivariate composite assessment model, in which all rare genetic variants of an individual are used to estimate the possibility of downstream events, which can be used to grade the risk of TNBC. At the genetic level, many tiny driving forces are counted together to determine the occurrence of certain downstream events, such as cancer. Our models give a very well-defined understanding of hereditary predispositions for TNBC. However, larger population-based prospective studies are required to validate these findings. With appropriate study populations, we can establish germline risk models for other pathological types, which could lead to general mechanisms. On the other hand, there is no patient in class 5 but 25% healthy people fall into this category, which indicates about a quarter of people have no risk of TNBC. Further research is needed to study whether these people have innate resistance that is coded by genetics to most type of cancers and to investigate the underlying mechanism of resistance to cancer. These results may revolutionize our current understanding of cancer and provide new strategy for realizing precision healthy. Figure 1 . Flow diagram illustrating the workflow developed for this study. GATK best practices workflow was used for variants calling on whole exome sequencing data.
Annotation was performed using ANNOVAR. Variants were filtered based on frequency and function. Then variants were mapped to genes and pathways for analysis. 
